. 2023 Nov 6;80(12):1295–1306. doi: 10.1001/jamaneurol.2023.4038

Table 1. Mediation Results^a.

	b (95% CI)^b	P value
ADNI
Global	0.15 (0.05 to 0.28)	.01^c
Braak I	0.03 (−0.09 to 0.14)	.68
Braak III	0.19 (0.07 to 0.32)	<.001^c
Braak IV	0.17 (0.06 to 0.30)	.01^c
Braak V	0.12 (0.01 to 0.24)	.03^c
Braak VI	0.09 (−0.02 to 0.21)	.11^c
Avid-A05
Global	0.33 (0.14 to 0.54)	<.001^c
Braak I	−0.02 (−0.17 to 0.13)	.78
Braak III	0.33 (0.14 to 0.54)	<.001^c
Braak IV	0.28 (0.11 to 0.48)	<.001^c
Braak V	0.34 (0.15 to 0.55)	<.001^c
Braak VI	0.27 (0.10 to 0.46)	<.001^c

Abbreviation: ADNI, Alzheimer’s Disease Neuroimaging Initiative.

^{^a}

The mediation models are controlled for age and sex. Additional mediation models correcting for diagnosis are shown in eTable 3 in Supplement 1.

^{^b}

Values are average causal mediation effect values derived from mediation analyses with apolipoprotein E ε4 risk as predictor, centiloid as mediator, and the annual tau standardized uptake value ratio rate of change in the respective Braak stage as the dependent variable.

^{^c}

Significant at false discovery rate–corrected P < .05.

Table 1. Mediation Resultsa.

Table 1. Mediation Results^a.